| Wen Bo Wang |
Wen Bo Wang is currently the Director at Standards Coordinating Body and the Senior Vice President-Technical Operations at Fate Therapeutics, Inc. He previously worked as an Associate Scientific Director at ViaCell, Inc. from 2001 to 2005 and as the Senior Vice President-Cell Therapy at FUJIFILM Cellular Dynamics, Inc. He holds a doctorate degree from Newcastle University and an undergraduate degree from Ocean University of China. |
| Bahram Valamehr |
Bahram Valamehr is currently the Chief Research & Development Officer at Fate Therapeutics, Inc. He started this position in 2021. Prior to his current role, he obtained an MBA from Pepperdine University in 2008. He also completed his undergraduate degree at the University of California Los Angeles Graduate School in 2000 and earned his doctorate from the same institution in 2009. |
| Edward J. Dulac |
Edward J. Dulac is currently the Chief Financial Officer & Accounting Officer at Fate Therapeutics, Inc. Prior to this, he worked as the Vice President-Business Development & Strategy at Celgene Corp. from 2017 to 2020. Before that, he was a Research Analyst at Barclays Capital, Inc. and Barclays Capital Securities Ltd. from 2009 to 2012. He also worked as a Principal at Pfizer (St. Louis) in 2007, Brooks Eckerd Pharmacy in 2001, and CVS, Inc. (Maryland) in 1999. Mr. Dulac received his undergraduate degree from the University of Pittsburgh in 1998 and his MBA from Kelley School of Business. |
| William H. Rastetter |
William H. Rastetter is the founder of Apoptos, Inc. (founded in 2007), Receptos LLC (founded in 2009), and GRAIL LLC (founded in 2015). He held the title of Chairman & Chief Executive Officer at Apoptos, Inc. in 2009, Executive Chairman at Receptos LLC from 2010 to 2015, and Director at GRAIL LLC from 2018 to 2021. His current job(s) include Chairman at Neurocrine Biosciences, Inc. since 2010, Chairman at Fate Therapeutics, Inc. since 2011, Chairman at Daré Bioscience, Inc. since 2014, Chairman at San Diego Squared, Director at CONNECT, Independent Director at Regulus Therapeutics, Inc. since 2013, Director at Entos, Inc., Advisor at Leerink Partners LLC, Trustee at California Institute of Technology, and Advisor at IIF Management Co. LLC. His former job(s) include Chairman & Chief Executive Officer at Celgene Corp. from 2009 to 2015, Chairman & Chief Executive Officer at IDEC Pharmaceuticals Corp. from 1986 to 2003, Executive Chairman at Biogen, Inc. from 1986 to 2005, Chairman at Illumina, Inc. from 1998 to 2016, Chairman at Cerulean Pharma, Inc. from 2014 to 2017, Executive Chairman at Biogen Idec, Inc. (North Carolina) from 2003 to 2005, Director-Corporate Ventures at Genentech, Inc. from 1982 to 1986, Partner at Venrock Associates from 2006 to 2013, and Faculty Member at Harvard University. He also served as an Associate Professor at Massachusetts Institute of Technology from 1975 to 1982 and is a Board of Trustees member at MPRD Ltd.His education includes graduate and doctorate degrees from Harvard University and an undergraduate degree from Massachusetts Institute of Technology. |
| J. Scott Wolchko |
J. Scott Wolchko is the founder of Fate Therapeutics, Inc., a company founded in 2007. He currently holds the title of President, Chief Executive Officer & Director at Fate Therapeutics, Inc. In addition to his founding position, Mr. Wolchko has held former positions at drugstore.com, Inc. as a Senior Director-Corporate Development. He also served as the Chief Financial Officer at Bocada LLC from 2001 to 2007. Furthermore, he worked at Morgan Stanley & Co. LLC as a Member-Investment Banking Health Care Group. Mr. Wolchko obtained a graduate degree from the University of Virginia and an undergraduate degree from the University of Vermont. |
| Michael Stewart Lee |
Michael Stewart Lee has founded Redmile Group LLC in 2007 where he holds the title of Managing Director. Currently, he holds multiple positions including Independent Director at Fate Therapeutics, Inc. since 2018, Director at Gilda's Club New York City, Inc., Independent Director at Shattuck Labs, Inc. since 2020, Independent Director at IGM Biosciences, Inc. since 2019, and Director at AgomAb Therapeutics NV. He previously worked as a Research Analyst at Welch Capital Partners LLC. Mr. Lee received an undergraduate degree from the University of Arizona. |
| Yuan J. Xu |
Yuan J. Xu is an Independent Director at Fate Therapeutics, Xilio Therapeutics, and Akero Therapeutics. Previously, Xu served as the Chief Executive Officer & Director at Legend Biotech Corp., General Manager & Vice President-Biologics at Gilead Sciences, Senior Vice President at Merck & Co., and Vice President at Novartis AG. Xu holds a doctorate from the University of Maryland and an undergraduate degree from Nanjing University. |
| Robert M. Hershberg |
Robert M. Hershberg was the founder of VentiRx Pharmaceuticals, Inc. founded in 2006, where he held the position of President, Chief Executive Officer & Director from 2012 to 2017. Currently, he holds multiple positions including Chairman, President & Chief Executive Officer at HilleVax, Inc. since 2020, Independent Director at Recursion Pharmaceuticals, Inc. since 2020, Independent Director at Fate Therapeutics, Inc. since 2020, and Independent Director at Adaptive Biotechnologies Corp. since 2013. He is also a Director at Cajal Neuroscience, Inc. and a Member at UW Medicine. He was also a Director at Guide Therapeutics, Inc. and held the position of Assistant Professor at Harvard Medical School. Dr. Hershberg has a doctorate degree from The Salk Institute for Biological Studies and undergraduate and doctorate degrees from the University of California, Los Angeles. |
| Timothy P. Coughlin |
Mr. Timothy P. Coughlin, CPA, is a Chairman at aTyr Pharma, Inc., an Independent Director at Travere Therapeutics, Inc. and an Independent Director at Fate Therapeutics, Inc. He is on the Board of Directors at Travere Therapeutics, Inc. and Fate Therapeutics, Inc. Mr. Coughlin was previously employed as a Chief Financial Officer by Neurocrine Biosciences, Inc., a Vice President-Financial Services by Catholic Health Initiatives, a Vice President-Financial Services by CommonSpirit Health (Illinois), and a Senior Manager-Health Sciences Practice by Ernst & Young LLP. He also served on the board at Peloton Therapeutics, Inc. He received his undergraduate degree from Temple University (Pennsylvania) and a graduate degree from San Diego State University. |
| Shefali Agarwal |
Shefali Agarwal is currently the Chairman, President & Chief Executive Officer at Valerio Therapeutics SA, an Independent Director at Fate Therapeutics, Inc., and an Independent Director at Gritstone bio, Inc. She previously served as the Chief Medical Officer at SQZ Biotechnologies Co. from 2017 to 2018 and as the Executive VP, Chief Medical & Development Officer at Epizyme, Inc. from 2018 to 2022. Dr. Agarwal holds a graduate degree from The Johns Hopkins University, a doctorate degree from Karnataka University, and a graduate degree from Merrick School of Business. |
| Karin Jooss |
Karin Jooss is an Independent Director at Fate Therapeutics, Inc. since 2019. She is also the Executive VP & Head of Research & Development at Gritstone bio, Inc. since 2021. Previously, she worked as the Vice President of Research at Cell Genesys, Inc. from 2005 to 2009 and as the Head of Cancer Immunotherapeutics at Pfizer Inc. from 2009 to 2016. Dr. Jooss holds a doctorate degree from Philipps University of Marburg. |
| Robert S. Epstein |
Robert S. Epstein founded Epstein Health LLC in 2012, where he is working as Chairman & Chief Executive Officer from 2012. Dr. Epstein also currently works at Veracyte, Inc., as Chairman, Illumina, Inc., as Independent Director from 2012, Fate Therapeutics, Inc., as Independent Director from 2014, Tasso, Inc., as Director, Intellos Health LLC, as Director, and Biologics & Biosimilars Collective Intelligence Consortium, as Managing Director from 2017. Dr. Epstein also formerly worked at Veracyte SD, Inc., as Chairman from 2019 to 2021, Proteus Digital Health, Inc., as Director from 2013 to 2020, AVEO Pharmaceuticals, Inc., as Independent Director in 2014, Drug Information Association, as Director, On-Q-ity, Inc., as Director from 2010 to 2014, International Society for Quality of Life Research, as Director, Mindstrong, Inc., as Director, Medco Health Solutions, Inc., as Chief Research & Development Officer from 2010 to 2012, Medco Research Institute LLC, as President from 2010 to 2012, Health Outcomes Research Europe SL, as President, and International Society for Pharmacoeconomics & Outcomes Rsch, as President from 1998 to 1999. Dr. Epstein received his graduate degree from the University of Maryland and undergraduate degree and doctorate degree from the University of Michigan. |
